Newsfile Corp
04 Aug 2026, 01:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Regeneron's Phase III Fianlimab-Libtayo study failed to reach statistical significance for its primary endpoint of progression-free survival. — Failure of a Phase III trial for a key drug candidate is a major fundamental blow to a biotech company's pipeline and future revenue.
-0.80A federal securities class action lawsuit has been filed alleging that Regeneron executives made false and misleading statements regarding the Fianlimab-Libtayo study. — Litigation regarding fraud and disclosure failures creates legal liability, reputational risk, and potential financial settlements.
-0.40The lawsuit claims the company concealed that preliminary statistical assumptions for the trial were flawed and that the active treatment arm lacked meaningful clinical differentiation. — Specific allegations of data manipulation or flawed assumptions undermine investor confidence in the company's overall clinical research integrity.
-0.30Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is facing a securities class action lawsuit following the failure of a Phase III clinical trial and allegations of misleading investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
